The weight loss injection starting with T: what tirzepatide is and what the evidence shows

What the trial data actually showed — and why regulators took notice

NICE's appraisal of tirzepatide (TA1026, published December 2024) drew heavily on the SURMOUNT-1 trial, which randomised 2,539 adults with obesity but without type 2 diabetes and followed them for 72 weeks. At the 15 mg maintenance dose, participants lost an average of around 20 to 21% of their starting body weight. That figure prompted NICE to recommend tirzepatide for NHS use in adults with a BMI of at least 35 alongside one or more weight-related conditions, with lower BMI thresholds applying for some ethnic backgrounds under NICE TA1026.

The head-to-head SURMOUNT-5 trial, published in the New England Journal of Medicine in 2025, compared tirzepatide directly with semaglutide 2.4 mg over 72 weeks in adults with obesity and found tirzepatide produced greater average weight reduction. That comparison matters for anyone weighing up the injection starting with T against the weight loss injection beginning with R, or any of the other licensed options, though which medicine suits a particular person is always a clinical question, not a ranking exercise.

One misconception worth setting straight: many people assume a higher trial result automatically means a better medicine for them personally. Body weight, other health conditions, how well you tolerate GI side effects, and whether you prefer an injection or a tablet all shape the prescriber's recommendation. The trial data inform that conversation; they don't replace it.

How two receptors differ from one, the mechanism behind the results

All GLP-1 receptor agonists slow gastric emptying and reduce appetite by mimicking a gut hormone released after eating. Tirzepatide does that, and it also activates the GIP receptor, a second pathway involved in insulin response and fat metabolism. This dual action is why tirzepatide is described as a dual agonist rather than simply a GLP-1 medicine.

In practical terms, the GIP component appears to enhance the appetite-suppressing effect and may reduce the severity of nausea compared with GLP-1-only injections at equivalent weight-loss doses, though individual responses vary. The NHS medicines page for tirzepatide covers the mechanism alongside common side effects and what to do if they occur, it is worth reading before starting treatment.

The six available strengths (2.5, 5, 7.5, 10, 12.5 and 15 mg) allow dose to be matched to tolerability and response over time. The 2.5 mg starting pen's job is adjustment, not weight loss; most of the therapeutic effect builds at higher doses reached after several months of titration. A prescriber manages that schedule based on how you respond at each stage.

Tirzepatide against the other licensed UK weight-loss injections

People searching for the weight loss injection starting with a letter are often trying to compare options. The injections currently licensed for weight management in the UK are tirzepatide (Mounjaro) and semaglutide (Wegovy, injection and now also tablet). The injections starting with M (Mounjaro and Mysimba, though Mysimba is a tablet not an injection) and the injection starting with S (semaglutide/Wegovy) all operate through appetite and satiety pathways, but differ in receptor targets, trial results and titration schedules. For a fuller picture of injections that help with weight loss in the UK, the receptor mechanism and licensed populations differ enough that a side-by-side read is useful before any consultation.

Ozempic is also semaglutide but is licensed for type 2 diabetes, not weight management, this distinction matters because prescribing it for weight loss alone is off-label. Saxenda (liraglutide) was another option but is not something nume dispenses. The question of which injection is right for your situation is one our prescribers consider individually for every patient, taking into account health history, current medicines and your goals.

How long any injection takes to produce noticeable results also varies. If you're curious about timelines, when weight-loss injections start working covers the evidence on early versus later response in plain terms.

Eligibility, safety monitoring, and what happens at a consultation

The licensed eligibility criteria for tirzepatide in private practice follow the SmPC: adults aged 18 or over with a BMI of 30 or above, or 27 or above if they have at least one weight-related condition such as hypertension, dyslipidaemia, obstructive sleep apnoea or type 2 diabetes. BMI alone does not guarantee a prescription; the prescriber reviews the complete clinical picture, including any medicines you currently take.

Safety monitoring matters throughout treatment. The most commonly reported side effects are gastrointestinal (nausea, loose stools, constipation, indigestion) typically most noticeable in the first weeks or after a dose increase, and usually settling with time. More serious but infrequent events include acute pancreatitis; the MHRA issued a Drug Safety Update in January 2026 highlighting severe, persistent stomach pain radiating to the back as a symptom requiring urgent medical attention. Suspected side effects should be reported through the MHRA's Yellow Card scheme. There is also a note worth knowing on oral contraceptives: women using the pill should add a non-oral method for the first four weeks of tirzepatide treatment and for four weeks after each dose increase, because gastric slowing may reduce pill absorption.

Tirzepatide is not licensed for use in pregnancy, breastfeeding or by anyone trying to conceive, and it is not licensed for those under 18. If you want to understand costs before booking anything, how much weight-loss injections cost gives an honest breakdown of what private treatment typically includes. For a broader look at the weight-loss injections available through a UK pharmacy, or to explore the full range of treatments, our weight-loss treatments overview is a useful starting point.

If tirzepatide sounds like it might be right for you, the next step is a proper clinical assessment. Speak to our prescribers through a free consultation, a named, GPhC-registered clinician reviews your answers the same day, not software.